Mesoblast Ltd (ASX: MSB) shares have had a stellar last month.
Mesoblast shares were trading at roughly $1.67 each on July 14 and closed yesterday trading at $2.32.
That's a good 38.92% rise for this healthcare stock.
For context, the S&P/ASX 200 Index (ASX: XJO) is up 3% in that same period.
Mesoblast is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
If you were fortunate enough to have invested $1,000 in Mesoblast shares a month ago, you would now be sitting with almost $390 profit.
Not bad for one month's work!
Image source: Getty Images
The Mesoblast rollercoaster
Despite this fast rise, Mesoblast shares have had a turbulent last year.
Since January, the share price is actually down 30%.
However, if you had bought a year ago, you would have seen a 141% rise.
That means if you invested $1,000 a year ago, your initial investment would now be worth $2,410.
For reference, the S&P/ASX 200 Health Care Index (ASX: XHJ) has risen less than 1% in the last 12 months.
Are Mesoblast shares a buy, hold, or sell?
Holders of Mesoblast shares have had to endure some serious volatility in recent times.
Mesoblast shares closed yesterday at $2.32 each, but were as low as $1.62 back in April.
However, it seems broadly speaking, brokers anticipate the share price to rise.
Broker Bell Potter has a speculative buy recommendation on the healthcare stock.
Bell Potter has a price target of $3.40, which indicates an enticing upside of 46.6%.
The broker acknowledged promising first-quarter revenue and optimism around the FDA approval for Ryoncil, which positions it as a critical treatment for children with steroid-refractory acute GVHD.
Elsewhere, brokerage platform Selfwealth still lists Mesoblast shares as undervalued, even after the big rise over the last month.
The platform has an average price target of $3.01 per share.
